Stock Exchange Company Of The Year News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Ryvu Therapeutics Reports First Quarter 2021 Financial Results
News provided by
Share this article
Share this article
KRAKOW, Poland, May 12, 2021 /PRNewswire/ Ryvu Therapeutics (WSE: RVU) reported today its first quarter 2021 financial results and provided a corporate update.
Q1 2021 was an eventful quarter for Ryvu and developments around RVU120 played a key role in it - commented Pawel Przewiezlikowski, Chief Executive Officer of Ryvu. We have submitted a clinical trial application to conduct a Phase I/II study of RVU120 in patients with solid tumors, and shortly after that we received an approval to expand the ongoing Phase I of RVU120 in AML and high risk MDS from US sites to Poland. We have also secured a non-dilutive grant to finance the RVU120 solid tumor study. Despite the recent partial clinical hold imposed on RVU120 Phase Ib study, we have achieved meaningful research progress in our clinical and pre-clinical pipeline in these first months of 2 ....

United States , Pawel Przewiezlikowski , Central Ethics Committee , National Center , Drug Administration , American Association Of Cancer Research , Warsaw Stock Exchange , Stock Exchange Company Of The Year , Development Ncbi , Warsaw Stock Exchange Company Of The Year , Office For Registration , Services Innovation , Office For Registration Of Medicinal Products , Chief Executive Officer , Clinical Trial Application , Polish Office , Medicinal Products , Medical Devices , Biocidal Products , Central Ethics , Ryvu Therapeutics , Acute Myeloid Leukemia , High Risk Myelodysplastic Syndrome , Warsaw Stock Exchange Company , Stock Exchange Company , American Association ,